VCVenkata Sushma Chamarthi

Venkata Sushma Chamarthi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Venkata Sushma Chamarthi has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Ultra-Processed Foods and Pediatric Obesity: A Clinical Case for Evidence-Based Action in Primary Care

    by Venkata Sushma Chamarthi, Jyothi Ranga Patri

    Ultra-processed foods (UPFs) are industrial formulations manufactured predominantly from refined ingredients and chemical additives. They are engineered to maximize palatability and shelf life. In the USA, UPFs now account for approximately 67% of total energy intake among children aged 2–19 years. This case study presents a composite de-identified clinical scenario of a 9-year-old boy presenting to primary care with obesity, elevated cardiometabolic markers, and a diet dominated by UPFs. The case draws on current evidence to examine the NOVA food classification system, socio-demographic drivers of UPF consumption, and health consequences spanning cardiometabolic, gut microbiome, neurodevelopmental, and oral health domains. Evidence-based screening tools and family-centered counseling approaches are discussed in the context of pediatric primary care. Policy responses at the school, community, and regulatory levels are also reviewed. This case study is intended for use in medical education, pediatric training, and continuing professional development across primary care, nutrition, dietetics, and public health. Information: © The Authors 2026

  • Open Access

    Wearable Devices in Pediatric Obesity: A Comprehensive Review of Current Applications and Future Directions

    by Jyothi Ranga Patri, Vignesh Gunasekaran, Shravan Gangula, Venkata Sushma Chamarthi

    Pediatric obesity represents a critical global public health crisis affecting millions of children and adolescents worldwide. Traditional obesity interventions face significant challenges related to adherence, engagement, and long-term efficacy. Wearable devices have emerged as promising tools for monitoring physical activity, metabolic parameters, and supporting behavior change in youth with obesity. This targeted literature review examines the current scope, applications, and effectiveness of wearable devices in managing childhood and adolescent obesity. We conducted a targeted literature review using PubMed and Google Scholar databases to identify studies published between 2010 and 2025. Search terms included wearable devices, pediatric obesity, activity trackers, accelerometers, continuous glucose monitors (CGMs), smartwatches, children, and adolescents. We focused on randomized controlled trials, systematic reviews, meta-analyses, and observational studies evaluating wearable devices in pediatric populations with obesity or overweight. Wearable devices demonstrate significant potential across multiple domains in pediatric obesity management. Activity trackers and accelerometers show effectiveness in increasing physical activity and improving anthropometric outcomes including body mass index (BMI), BMI z-score, and body fat percentage. Consumer-grade devices like Fitbit and research-grade accelerometers have shown acceptable accuracy and feasibility in pediatric populations. CGMs are emerging as valuable tools for understanding glycemic variability and supporting dietary behavior change in youth with obesity. Heart rate monitors and smartwatches provide real-time biofeedback that enhances engagement. However, heterogeneity in device types, intervention duration, and outcome measures limits definitive conclusions. In conclusion, wearable devices represent a versatile and increasingly accessible approach to pediatric obesity management. While current evidence supports their use for physical activity promotion and metabolic monitoring, significant gaps remain regarding long-term adherence, optimal implementation strategies, and integration into clinical care pathways. Future research should focus on standardizing outcome measures, evaluating cost-effectiveness, and developing age-appropriate interventions that maximize the unique potential of wearable technology in combating the pediatric obesity epidemic.

  • Open Access

    Artificial Intelligence Applications in Pediatric Obesity Medicine: Bridging Predictive Analytics, Clinical Decision Support, and Family-Centered Care

    by Jyothi Ranga Patri, Mahika Shetty, Venkata Sushma Chamarthi

    Childhood obesity represents a significant public health challenge, affecting over 340 million children and adolescents worldwide. Despite the implementation of various intervention strategies, prevalence rates continue to rise. Artificial intelligence (AI) technologies offer considerable potential to address this crisis by enhancing risk prediction and individualizing treatment plans through scalable, family-oriented interventions. This review examines current evidence regarding AI applications in pediatric obesity medicine, with a focus on clinical utility, evaluation, and recommendations for future implementation. A comprehensive narrative review of the peer-reviewed literature was conducted to evaluate the applications of AI in pediatric obesity care. The review encompassed predictive analytics, clinical decision support systems (CDSS), remote monitoring technologies, and natural language processing (NLP) tools. PubMed, Scopus, and IEEE databases were systematically searched for studies published between 2015 and 2024 with a focus on validated AI systems with demonstrated clinical applications in pediatric populations. Studies were identified using combinations of keywords including “artificial intelligence,” “machine learning,” “deep learning,” “pediatric obesity,” “clinical decision support,” “predictive analysis,” “telemedicine,” “remote monitoring,” and “natural language processing.” Inclusion criteria included peer-reviewed English-language publications that described AI applications with relevance to pediatric obesity screening, prevention, or management. Studies were excluded if they addressed adult populations exclusively or focused on AI methodology without clinical application. Reference lists of relevant articles were also reviewed to identify additional eligible studies. Two authors (JRP and VSC) independently screened titles and abstracts, with discrepancies resolved through discussion. It is important to note that no AI system is currently approved or used in routine pediatric obesity clinical care; most applications described in this review remain in research or early pilot phases. AI applications demonstrate significant potential in managing various aspects of pediatric obesity. Machine learning algorithms facilitate earlier identification of high-risk children, achieving 75–90% accuracy in predicting obesity risk, as reported in studies employing logistic regression, random forest, and gradient boosting models on longitudinal electronic health record datasets. CDSS can generate effective treatment recommendations tailored to individual metabolic profiles, behavioral patterns, and family circumstances. Remote monitoring platforms that incorporate wearable devices and mobile health applications enable patient engagement and real-time adjustments to interventions. Automated screening and documentation through NLP tools may reduce clinician workload and enhance care quality. However, major implementation challenges include algorithmic bias, data breach risks, limited interoperability, and disparities in patient access to technology. AI applications enhance prediction accuracy, enable personalized interventions, and increase scalability, thereby offering substantial opportunities to advance pediatric obesity care. Key steps for effective integration involve addressing technical challenges, enhancing equity and access, ensuring clinical oversight, and adhering to family-centered care principles. Future research should prioritize improving validation across diverse populations by assessing long-term outcomes and developing implementation frameworks that support, rather than replace, the therapeutic relationship between communities and healthcare providers.

  • Open Access

    Treat-to-Target Strategies and Early Biologic Initiation in Polyarticular Juvenile Idiopathic Arthritis: Translating Evidence into Clinical Practice

    by Jyothi Ranga Patri, Sastry Chamarthi, Venkata Sushma Chamarthi

    Juvenile idiopathic arthritis (JIA) is among the most prevalent chronic inflammatory rheumatic diseases in children. Over the past two decades, the treatment landscape has evolved significantly with the introduction of biologic disease-modifying antirheumatic drugs and the adoption of treat-to-target strategies aimed at achieving clinically inactive disease. Early initiation of biologic therapies can facilitate rapid disease control and improve long-term outcomes. However, the implementation and integration of newer treatments within the current healthcare system are often hindered by insurance authorization requirements, high costs, and variability in clinical practice. This review evaluates current evidence-based approaches supporting the treat-to-target strategy and early biologic intervention in polyarticular JIA. Additionally, it discusses the practical challenges of translating evidence into routine clinical care and proposes sustainable strategies to optimize treatment outcomes while addressing existing knowledge and practice gaps.


  • Pediatric Obesity Treatment: From Paradigm Shift to Implementation Challenges

    by Venkata Sushma Chamarthi, Evan P. Nadler

  • Open Access

    Brucellosis presenting as prolonged fever of unknown origin in a two-year-old child: a diagnostic challenge

    by Pranavi Bandaru, Mahika Shetty, Ventaka Sushma Chamarthi, Vignesh Gunasekaran, Jyothi Patri

    Brucellosis is a zoonotic disease with diverse clinical manifestations and is an uncommon but important cause of prolonged fever in children. Diagnosis may be delayed due to nonspecific symptoms, limited exposure history, and variable serologic findings. This report describes a two-year-old patient who experienced 17 days of recurrent fever associated with fatigue, myalgia, and diarrhea following a horse-related injury two months earlier. Extensive evaluation demonstrated elevated inflammatory markers, thrombocytosis, cervical lymphadenopathy, and hepatic lesions, but the etiology was unrevealing. A thorough exposure history prompted targeted zoonotic testing, which identified Brucella-positive IgM in the absence of detectable IgG, consistent with an acute Brucella infection in the appropriate clinical context. This case highlights the importance of detailed exposure history and consideration of brucellosis in the differential diagnosis of pediatric fever of unknown origin (FUO), even in the absence of classic presentation.

  • Open Access

    Vascular ring presenting as failure to thrive

    by Venkata Sushma Chamarthi, Sastry Chamarthi

    A 6-month-old female presented with persistent post-prandial vomiting and poor weight gain despite adequate caloric intake. Physical examination revealed an emaciated but otherwise stable infant. Laboratory findings were normal. A barium esophagogram demonstrated posterior esophageal indentation suggestive of extrinsic compression, and computed tomography angiography revealed a right-sided aortic arch with retroesophageal Kommerell diverticulum and aberrant left subclavian artery – completing a vascular ring. Surgical division of the ligamentum arteriosum led to rapid symptom resolution and catch-up growth. This case underscores the importance of considering vascular rings in infants with unexplained feeding difficulties or failure to thrive, even in the absence of respiratory symptoms. Keywords: Vascular ring, Kommerell diverticulum, Failure to thrive

  • Open Access

    A call for responsible innovation in pediatric health care

    by Venkata Sushma Chamarthi, Ramandeep Kaur, Rahul Kashyap

    Artificial intelligence (AI) is transforming healthcare by equipping clinicians and patients with tools that support more efficient, patient-centered care. In pediatrics, however, the implementation of AI demands a higher threshold for responsibility, transparency, and family-centered engagement. This perspective explores the opportunities and challenges of AI in pediatric healthcare, highlighting the unique ethical and developmental considerations that distinguish children’s care from adult medicine. Drawing on Kaiser Permanente’s seven principles for responsible AI, the article emphasizes the importance of augmentation over automation, the need for pediatric-specific validation, and the necessity of trustworthiness and fairness in clinical deployment. It outlines how AI can support primary care providers through enhanced decision support, early screening for developmental and behavioral disorders, including the potential for AI to create personalized developmental trajectories, moving beyond static population norms to provide earlier, more precise insights into a child’s neurodevelopmental progress, improved electronic health record usability, and risk prediction models. However, without careful governance, AI poses risks of bias, inequity, and erosion of clinician judgment. Policy recommendations include redesigning family consent models, ensuring robust clinician training, and mandating pediatric-specific testing of AI systems with diverse, representative datasets. Ultimately, AI should function as a supportive tool that strengthens, not replaces, human empathy, clinical expertise, and family-centered values. Responsible innovation is essential to ensure that children benefit equitably from AI while maintaining trust, safety, and compassion in pediatric healthcare.


  • Open Access

    The Evolving Landscape of Respiratory Syncytial Virus (RSV) Prophylaxis in Infants

    by Sastry Chamarthi, Surendra Gupta, Venkata Sushma Chamarthi

    Throughout human history, respiratory infections have been among the most common illnesses affecting populations worldwide. Respiratory syncytial virus (RSV) is recognized as one of the major pathogens responsible for a significant disease burden in young children and the elderly population, causing lower respiratory tract infections. Initially identified as the chimpanzee coryza virus in the mid-20th century, it was later named human RSV. This review outlines the discovery of RSV, the initial challenges faced in vaccine development, and the evolution of monoclonal antibodies for infants and vaccines for pregnant mothers to prevent RSV infection in infants. Early vaccine trials enhanced respiratory disease and increased mortality among vaccinated infants. There were subsequent failures with live attenuated vaccines. Research turned toward developing the monoclonal antibody palivizumab, which provided the first practical means of protecting high-risk infants against RSV infection. Subsequent advances in monoclonal antibodies, especially nirsevimab, and the advent of the maternal vaccination program with the Bivalent Prefusion F Vaccination have expanded disease prevention to the population level instead of targeting high-risk infants. These advances promise to reduce hospitalizations and severe disease, improving overall community health. Future priorities include ensuring equitable access, maintaining long-term safety surveillance, and integrating RSV prevention into national immunization programs worldwide.